Cargando…

Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes

BACKGROUND: The identification of circulating biomarkers associated with the risk of type 2 diabetes (T2D) is useful for improving the current prevention strategies in the most at-risk patients. Here, we aimed to investigate the association of plasma apolipoprotein concentrations in prediabetes subj...

Descripción completa

Detalles Bibliográficos
Autores principales: Croyal, Mikaël, Wargny, Matthieu, Chemello, Kevin, Chevalier, Chloé, Blanchard, Valentin, Bigot-Corbel, Edith, Lambert, Gilles, Le May, Cédric, Hadjadj, Samy, Cariou, Bertrand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822824/
https://www.ncbi.nlm.nih.gov/pubmed/35130909
http://dx.doi.org/10.1186/s12933-022-01452-5
_version_ 1784646680309661696
author Croyal, Mikaël
Wargny, Matthieu
Chemello, Kevin
Chevalier, Chloé
Blanchard, Valentin
Bigot-Corbel, Edith
Lambert, Gilles
Le May, Cédric
Hadjadj, Samy
Cariou, Bertrand
author_facet Croyal, Mikaël
Wargny, Matthieu
Chemello, Kevin
Chevalier, Chloé
Blanchard, Valentin
Bigot-Corbel, Edith
Lambert, Gilles
Le May, Cédric
Hadjadj, Samy
Cariou, Bertrand
author_sort Croyal, Mikaël
collection PubMed
description BACKGROUND: The identification of circulating biomarkers associated with the risk of type 2 diabetes (T2D) is useful for improving the current prevention strategies in the most at-risk patients. Here, we aimed to investigate the association of plasma apolipoprotein concentrations in prediabetes subjects with the incidence of new-onset T2D during follow-up. METHODS: In the IT-DIAB prospective study, 307 participants with impaired fasting glucose levels (fasting plasma glucose [FPG]: 110–125 mg/dL) were followed yearly for 5 years. The onset of T2D was defined as a first FPG value ≥ 126 mg/dL during follow-up. Apolipoprotein (apo)A-I, A-II, A-IV, B100, C-I, C-II, C-III, C-IV, D, E, F, H, J, L1, M, and (a) plasma concentrations were determined by mass spectrometry. Correlations between apolipoproteins and metabolic parameters at baseline were assessed by Spearman’s coefficients. Kaplan–Meier curves were drawn using a ternary approach based on terciles and incident T2D. The association between plasma apolipoproteins concentrations and the incidence of T2D was determined using Cox proportional-hazards models. RESULTS: During a median follow-up of 5-year, 115 participants (37.5%) developed T2D. After adjustment for age, sex, body mass index, FPG, HbA(1c), and statin use, the plasma levels of apoC-I, apoC-II, apoC-III, apoE, apoF, apoH, apoJ, and apoL1 were positively associated with a high risk for T2D. After further adjustment for plasma triglycerides, only apoE (1 SD natural-log-transformed hazard ratio: 1.28 [95% confidence interval: 1.06; 1.54]; p = 0.010), apoF (1.22 [1.01; 1.48]; p = 0.037), apoJ (1.24 [1.03; 1.49]; p = 0.024), and apoL1 (1.26 [1.05; 1.52]; p = 0.014) remained significantly associated with the onset of T2D. Kaplan–Meier survival curves also showed that the lower third of plasma apoE levels (< 5.97 mg/dL) was significantly associated with a lower risk of conversion to T2D (log-rank test, p = 0.002) compared to the middle and upper thirds. CONCLUSIONS: The plasma apoE levels are positively associated with the risk of T2D in prediabetes subjects, independently of traditional risk factors. The possible associations of apoF, apoJ, and apoL1 with T2D risk also pave the way for further investigations. Trial registration This trial was registered at clinicaltrials.gov as NCT01218061 and NCT01432509 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-022-01452-5.
format Online
Article
Text
id pubmed-8822824
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88228242022-02-08 Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes Croyal, Mikaël Wargny, Matthieu Chemello, Kevin Chevalier, Chloé Blanchard, Valentin Bigot-Corbel, Edith Lambert, Gilles Le May, Cédric Hadjadj, Samy Cariou, Bertrand Cardiovasc Diabetol Original Investigation BACKGROUND: The identification of circulating biomarkers associated with the risk of type 2 diabetes (T2D) is useful for improving the current prevention strategies in the most at-risk patients. Here, we aimed to investigate the association of plasma apolipoprotein concentrations in prediabetes subjects with the incidence of new-onset T2D during follow-up. METHODS: In the IT-DIAB prospective study, 307 participants with impaired fasting glucose levels (fasting plasma glucose [FPG]: 110–125 mg/dL) were followed yearly for 5 years. The onset of T2D was defined as a first FPG value ≥ 126 mg/dL during follow-up. Apolipoprotein (apo)A-I, A-II, A-IV, B100, C-I, C-II, C-III, C-IV, D, E, F, H, J, L1, M, and (a) plasma concentrations were determined by mass spectrometry. Correlations between apolipoproteins and metabolic parameters at baseline were assessed by Spearman’s coefficients. Kaplan–Meier curves were drawn using a ternary approach based on terciles and incident T2D. The association between plasma apolipoproteins concentrations and the incidence of T2D was determined using Cox proportional-hazards models. RESULTS: During a median follow-up of 5-year, 115 participants (37.5%) developed T2D. After adjustment for age, sex, body mass index, FPG, HbA(1c), and statin use, the plasma levels of apoC-I, apoC-II, apoC-III, apoE, apoF, apoH, apoJ, and apoL1 were positively associated with a high risk for T2D. After further adjustment for plasma triglycerides, only apoE (1 SD natural-log-transformed hazard ratio: 1.28 [95% confidence interval: 1.06; 1.54]; p = 0.010), apoF (1.22 [1.01; 1.48]; p = 0.037), apoJ (1.24 [1.03; 1.49]; p = 0.024), and apoL1 (1.26 [1.05; 1.52]; p = 0.014) remained significantly associated with the onset of T2D. Kaplan–Meier survival curves also showed that the lower third of plasma apoE levels (< 5.97 mg/dL) was significantly associated with a lower risk of conversion to T2D (log-rank test, p = 0.002) compared to the middle and upper thirds. CONCLUSIONS: The plasma apoE levels are positively associated with the risk of T2D in prediabetes subjects, independently of traditional risk factors. The possible associations of apoF, apoJ, and apoL1 with T2D risk also pave the way for further investigations. Trial registration This trial was registered at clinicaltrials.gov as NCT01218061 and NCT01432509 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-022-01452-5. BioMed Central 2022-02-07 /pmc/articles/PMC8822824/ /pubmed/35130909 http://dx.doi.org/10.1186/s12933-022-01452-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Original Investigation
Croyal, Mikaël
Wargny, Matthieu
Chemello, Kevin
Chevalier, Chloé
Blanchard, Valentin
Bigot-Corbel, Edith
Lambert, Gilles
Le May, Cédric
Hadjadj, Samy
Cariou, Bertrand
Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes
title Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes
title_full Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes
title_fullStr Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes
title_full_unstemmed Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes
title_short Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes
title_sort plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822824/
https://www.ncbi.nlm.nih.gov/pubmed/35130909
http://dx.doi.org/10.1186/s12933-022-01452-5
work_keys_str_mv AT croyalmikael plasmaapolipoproteinconcentrationsandincidentdiabetesinsubjectswithprediabetes
AT wargnymatthieu plasmaapolipoproteinconcentrationsandincidentdiabetesinsubjectswithprediabetes
AT chemellokevin plasmaapolipoproteinconcentrationsandincidentdiabetesinsubjectswithprediabetes
AT chevalierchloe plasmaapolipoproteinconcentrationsandincidentdiabetesinsubjectswithprediabetes
AT blanchardvalentin plasmaapolipoproteinconcentrationsandincidentdiabetesinsubjectswithprediabetes
AT bigotcorbeledith plasmaapolipoproteinconcentrationsandincidentdiabetesinsubjectswithprediabetes
AT lambertgilles plasmaapolipoproteinconcentrationsandincidentdiabetesinsubjectswithprediabetes
AT lemaycedric plasmaapolipoproteinconcentrationsandincidentdiabetesinsubjectswithprediabetes
AT hadjadjsamy plasmaapolipoproteinconcentrationsandincidentdiabetesinsubjectswithprediabetes
AT carioubertrand plasmaapolipoproteinconcentrationsandincidentdiabetesinsubjectswithprediabetes